Clinical trials
Advanced Solid Tumor clinical trials
Below are recruiting advanced solid tumor clinical trials, each written for real people, not researchers. We’re tracking 1,397 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06459973RecruitingPhase 1/Phase 2
Study of YL205 for advanced solid tumors
This trial tests a new drug called YL205 for people with certain advanced cancers that have a specific protein (Napi2b) on their cells. It aims to see if the drug is safe and effective.
Denver, ColoradoAges 18 years+ - NCT07123415RecruitingPhase 1
Study of APX-343A alone or with pembrolizumab for advanced solid tumors
This trial tests a new drug called APX-343A, either by itself or in combination with the immunotherapy pembrolizumab, for people with advanced solid tumors that have not responded to prior treatments.
SeongnamAges 19 years+ - NCT06016062RecruitingPhase 1/Phase 2
Study of RC148 for advanced solid tumors
This trial tests a new drug called RC148, both alone and combined with other treatments, for people with advanced solid tumors that haven't responded to standard therapy. It includes several groups for specific cancers (like non-small cell lung, cervical, stomach, and ovarian cancer) to see if RC148 can shrink tumors or slow their growth.
AnhuiAges 18 years+ - NCT07512583RecruitingPhase 1/Phase 2
TQB2930 injection for advanced solid tumors with HER2 expression
This study tests a new injection called TQB2930 designed to treat advanced solid cancers (cancers that have spread) that have HER2 protein on their surface. The goal is to see if this treatment can shrink these tumors and help patients live longer.
Beijing, Beijing MunicipalityAges 18–75 - NCT05584670RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This is an early (Phase 1/2) study of SAR445877, a new drug, in adults with advanced or metastatic solid cancers. It aims to find the safest dose and learn whether it can shrink tumors or help control disease when standard treatments aren’t available or no longer work.
Newark, DelawareAges 18 years+ - NCT07466160RecruitingPhase 1/Phase 2
Study of two experimental drugs for advanced solid tumors
This trial tests a new combination of two investigational drugs, 7MW3711 and JS207, for people with advanced solid tumors that no longer respond to standard treatments. It aims to see if this combination is safe and effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04412616RecruitingPhase 1
Study drug for advanced EGFR-positive solid tumors
This early-phase trial tests a new drug (ZZ06) in adults with advanced solid cancers that have an EGFR “positive” tumor test result. It’s for people whose cancer has grown despite standard treatment or who don’t have a standard option.
Los Angeles, CaliforniaAges 18 years+ - NCT06963281RecruitingPhase 1
Study of an experimental drug for late-stage solid tumors
This trial tests an experimental drug called IBI3020 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective for these patients.
Pheonix, ArizonaAges 18–75 - NCT07182591RecruitingPhase 1
Study of DS5361b for advanced solid tumors with high TMB or MSI
This study tests a new drug (DS5361b) for people with advanced solid tumors that have high genetic instability (TMB-H or MSI-H). It aims to see if the drug can shrink tumors or slow their growth.
Sarasota, FloridaAges 18 years+ - NCT05785754RecruitingPhase 1
Early drug study for advanced solid tumors
This Phase 1 study tests DCSZ11 in people with advanced or metastatic solid tumors (cancers that can’t be removed or have spread) given alone or with other treatments. It’s designed to find a safe dose and to see whether the treatment shows signs of shrinking cancer.
Birmingham, AlabamaAges 18 years+ - NCT07131202RecruitingPhase 1/Phase 2
FL115 plus PD-1 antibody for advanced solid tumors
This trial tests a new drug called FL115 combined with an immunotherapy (PD-1 antibody) for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if this combination can shrink tumors or slow their growth.
Guangzhou, GuangdongAges 18–80 - NCT07399769RecruitingPhase 1/Phase 2
MSLN CAR-T therapy for advanced solid tumors
This trial tests a new immune cell therapy called MSLN CAR-T for people with advanced solid tumors that have spread or cannot be removed by surgery. It may help if your cancer has not responded to standard treatment and tests positive for a protein called mesothelin (MSLN).
Shenzhen, Other (Non U.s.)Ages 18–75 - NCT06241898RecruitingPhase 1
First study of a new drug for advanced solid tumors
This study tests a new drug (BB-1709) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it's safe and how well it works.
Beijing, Beijing MunicipalityAges 18–78 - NCT07071090RecruitingPhase 1
Study of DC50292A for advanced solid tumors with MTAP deletion
This trial tests a new tablet, DC50292A, for people whose cancer has an MTAP gene deletion. It is for patients whose cancer has spread or returned and who have not had success with other treatments.
Fuzhou, FujianAges 18 years+ - NCT06589401RecruitingPhase 1
Oral paclitaxel for advanced solid tumors
This trial tests an oral form of paclitaxel for people with advanced solid tumors, including breast cancer. It aims to see if swallowing the drug is safe and effective when standard treatments no longer work.
Barcelona, CataloniaAges 18 years+ - NCT07407504RecruitingPhase 1
GenSci145 for advanced solid tumors with PIK3CA mutation
This trial tests a new oral drug, GenSci145, alone or with other drugs, for people whose advanced cancer has a PIK3CA gene change and has grown after standard treatments. It aims to see if this drug can help shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT05877664RecruitingPhase 1
Test drug ZG0895.HCl in advanced solid tumors
This Phase 1 trial studies ZG0895.HCl, a new experimental treatment, in people with advanced solid cancers. It’s mainly to check safety and how the body responds, and it may help by shrinking or controlling tumors if the drug works.
Zhejiang, HangzhouAges 18–75 - NCT06933069RecruitingPhase 1
Safety study of CMAB017 for advanced solid tumors
This trial tests a new drug called CMAB017 for people with advanced solid tumors who have run out of standard options. The goal is to find a safe dose and see how well it is tolerated.
ShanghaiAges 18–75 - NCT07396584RecruitingPhase 1/Phase 2
HMPL-A580 for advanced or metastatic solid tumors
This trial tests a new drug called HMPL-A580 in people with advanced or metastatic solid tumors that cannot be removed by surgery. The goal is to see if it is safe and effective.
Orange, CaliforniaAges 18 years+ - NCT05636215RecruitingPhase 1/Phase 2
Testing a new HER2-targeted drug for advanced solid tumors
This early-phase study tests a new investigational drug (IBI354) in people with advanced or metastatic solid cancers that have HER2 changes. It’s mainly meant to find out how the drug works in the body and whether it’s safe enough to keep studying.
Randwick, New South WalesAges 18 years+ - NCT03891706RecruitingPhase 1
Personalized T-cell therapy for advanced solid tumors
This early-phase study tests personalized immune cells (T cells) made from your own tumor and blood to treat advanced solid cancers. It may help your immune system recognize and attack your tumor, especially if standard treatments no longer work.
Guangzhou, GaungdongAges 18–70 - NCT07606612RecruitingPhase 1
Testing SI-B036 in Advanced Solid Tumors
This early-stage trial tests a new drug called SI-B036 in patients with advanced cancers that have spread or cannot be completely removed by surgery. The goal is to understand how safe the drug is and how well it works.
Guangzhou, GuangdongAges 18–75 - NCT07102004RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial tests an experimental drug for people with advanced solid tumors, including small cell lung cancer, that have stopped responding to standard treatments. The goal is to find out if the drug is safe and effective.
BeijingAges 18 years+ - NCT04999384RecruitingPhase 1
First-in-human dose study for advanced cancers using AN4005
This early study tests AN4005 in adults with advanced or hard-to-treat solid tumors or certain lymphomas. The goal is to find a safe dose and see how the treatment behaves in the body.
Hackensack, New JerseyAges 18 years+
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced solid tumor?
- Yes. Clin2 currently lists 1,397 recruiting advanced solid tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced solid tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced solid tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.